A subsequent RCT indicated that an angiotensin II receptor blocker reduced hepatic vascular resistance in patients with compensated cirrhosis, thereby improving portal venous outflow and highlighting its potential therapeutic role in modulating the renin-angiotensin system in this patient population [234]. This evidence concerns the gene REN and Cirrhosis.